For a rising portfolio

Learn everything you need to know in 'How to Find the Best Growth Stocks' for FREE from The Successful Investor.

Canadian Growth Stocks: CGI Group, CAE Inc., Fortis Inc. Stock and more.

 I consent to receiving information from The Successful Investor via email. I understand I can unsubscribe from these updates at any time.

Topic: Growth Stocks

Growth stocks: Cash-rich U.S. drug distributor making big inroads in Canada

Growth Stocks: McKesson ROBOT-Rx image

Yesterday, we discussed U.S. drug store chain Walgreen, a name familiar to many Canadian investors. Today we examine a U.S. drug distributor that has a strong and growing Canadian presence, but is not as well known. We first included this stock in the Aggressive Growth portfolio of Wall Street Stock Forecaster in June, 2002.

McKesson Corp. (New York symbol MCK; www.mckesson.com) is the largest wholesale drug distributor in the U.S. and Canada. It also owns 49% of Mexico’s largest drug distributor.

McKesson’s customers include 40,000 pharmacies, as well as doctor’s offices, hospitals and clinics. The company also supplies surgical tools and health and beauty products.

McKesson’s revenue rose 20.6%, from $93.0 billion in 2007 to $112.1 billion in 2011 (fiscal years end March 31). Earnings jumped 49.4%, from $881 million in 2007 to $1.3 billion in 2011. Because of fewer shares outstanding, earnings per share shot up 73.0%, from $2.89 in 2007 to $5.00 in 2011.

A big part of the company’s growth comes from its technology solutions division, which makes computers and software that help pharmacies and clinics manage their drug inventories. This division accounts for just 3% of McKesson’s revenue, but supplies close to 25% of its earnings.

Save $50.00 and get our #1 U.S. Stock Pick of the Year

Pat McKeough has unveiled his #1 U.S. Stock Pick for 2012, the American stock he believes has the best chance for explosive gains in the coming year. As a subscriber to The Successful Investor Network Daily, we would like to offer you this opportunity to get all the details on this stock when you accept a no-risk trial subscription to our advisory on U.S. stocks written especially for Canadian investors, Wall Street Stock Forecaster.

When you accept this special offer you will save a full $50.00 off the regular annual subscription rate PLUS you can download all the details on Pat’s number one stock pick in the complete Wall Street Stock Forecaster archive.

Plus in the latest issue you get our advice and recommendations on 21 more stocks with exceptional growth potential. Best of all, you can save $50.00 on a no-risk introductory subscription to one full year (12 issues) of Wall Street Stock Forecaster. Plus you get our weekly hotline updates, 3 years of back issues and much, much more. Click here to take advantage of this offer.

Growth stocks: McKesson makes Canadian acquisition, has room for more

Acquisitions have also fuelled McKesson’s earnings. In December 2010, it bought US Oncology, a privately held firm that sells drugs and provides research and administrative services to over 500 cancer care facilities in the U.S.

In January 2012, McKesson agreed to pay $920 million (Canadian) for Drug Trading Company Limited, which buys drugs on behalf of 850 independently owned pharmacies in Canada. McKesson already distributes products to these customers; that familiarity cuts the risk of this purchase. The deal should close in mid-2012.

COMMENTS PLEASE

When you come across a company in your daily life that impresses you as a particularly smart or dumb organization, do you do an Internet search to find out if you can invest in it? Have you ever bought or sold a stock because of your personal interaction with the company? How did that work out?
Click here

The company’s capital expenditures are low, and it spends less than 1% of its revenue on research. That gives McKesson plenty of flexibility to keep making acquisitions. It also holds cash of $4.2 billion, or $17.03 a share, and its long-term debt is just $3.6 billion, or 17% of its market cap.

In addition to acquisitions, McKesson is using its cash to buy back shares. It recently added $650 million to its share repurchase authorization. It can now buy back up to $1.5 billion of its stock. There is no time limit to these purchases. The company is also likely to raise its dividend again this year. The current annual rate of $0.80 a share yields 0.9%.

McKesson will probably earn $6.05 a share in fiscal 2012. The stock trades at a reasonable 14.6 times that estimate.

In the latest edition of Wall Street Stock Forecaster, we look at whether McKesson can continue to increase its earnings in the face of stiff competition to renew its contract as sole supplier of drugs to the U.S. Department of Veterans Affairs. We conclude with our clear buy-hold-sell advice on the stock.

You can get Wall Street Stock Forecaster, with our advice on leading U.S. stocks written especially for Canadian investors, along with “My #1 U.S. Stock Pick for 2012” as well as FREE access to our weekly Email/Telephone Hotlines when you subscribe now. And as a new subscriber you can save $50.00 on an introductory subscription. Click here to get started right away.

Comments

Tell Us What YOU Think

You must be logged in to post a comment.

Please be respectful with your comments and help us keep this an area that everyone can enjoy. If you believe a comment is abusive or otherwise violates our Terms of Use, please click here to report it to the administrator.